Logo image of BNGO

BIONANO GENOMICS INC (BNGO) Stock Fundamental Analysis

NASDAQ:BNGO - Nasdaq - US09075F3055 - Common Stock - Currency: USD

4.08  -0.02 (-0.49%)

After market: 3.88 -0.2 (-4.9%)

Fundamental Rating

2

Taking everything into account, BNGO scores 2 out of 10 in our fundamental rating. BNGO was compared to 56 industry peers in the Life Sciences Tools & Services industry. BNGO may be in some trouble as it scores bad on both profitability and health. BNGO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BNGO has reported negative net income.
BNGO had a negative operating cash flow in the past year.
BNGO had negative earnings in each of the past 5 years.
In the past 5 years BNGO always reported negative operating cash flow.
BNGO Yearly Net Income VS EBIT VS OCF VS FCFBNGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -155.43%, BNGO is doing worse than 96.36% of the companies in the same industry.
Looking at the Return On Equity, with a value of -277.86%, BNGO is doing worse than 89.09% of the companies in the same industry.
Industry RankSector Rank
ROA -155.43%
ROE -277.86%
ROIC N/A
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
BNGO Yearly ROA, ROE, ROICBNGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BNGO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BNGO Yearly Profit, Operating, Gross MarginsBNGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

BNGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNGO has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BNGO has been increased compared to 5 years ago.
BNGO has a worse debt/assets ratio than last year.
BNGO Yearly Shares OutstandingBNGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
BNGO Yearly Total Debt VS Total AssetsBNGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -13.43, we must say that BNGO is in the distress zone and has some risk of bankruptcy.
BNGO has a Altman-Z score of -13.43. This is amonst the worse of the industry: BNGO underperforms 94.55% of its industry peers.
BNGO has a Debt/Equity ratio of 0.07. This is a healthy value indicating a solid balance between debt and equity.
BNGO has a better Debt to Equity ratio (0.07) than 69.09% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -13.43
ROIC/WACCN/A
WACC18.42%
BNGO Yearly LT Debt VS Equity VS FCFBNGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

BNGO has a Current Ratio of 1.43. This is a normal value and indicates that BNGO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.43, BNGO is doing worse than 74.55% of the companies in the same industry.
A Quick Ratio of 0.99 indicates that BNGO may have some problems paying its short term obligations.
BNGO's Quick ratio of 0.99 is on the low side compared to the rest of the industry. BNGO is outperformed by 78.18% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.99
BNGO Yearly Current Assets VS Current LiabilitesBNGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BNGO have decreased strongly by -1339.03% in the last year.
The Revenue has decreased by -0.85% in the past year.
BNGO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.65% yearly.
EPS 1Y (TTM)-1339.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2300%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-34.83%

3.2 Future

BNGO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.12% yearly.
Based on estimates for the next years, BNGO will show a very strong growth in Revenue. The Revenue will grow by 30.99% on average per year.
EPS Next Y-2022.13%
EPS Next 2Y-82.71%
EPS Next 3Y-30.56%
EPS Next 5Y29.12%
Revenue Next Year-19.94%
Revenue Next 2Y-10.61%
Revenue Next 3Y-1.87%
Revenue Next 5Y30.99%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BNGO Yearly Revenue VS EstimatesBNGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
BNGO Yearly EPS VS EstimatesBNGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BNGO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BNGO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNGO Price Earnings VS Forward Price EarningsBNGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNGO Per share dataBNGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

BNGO's earnings are expected to decrease with -30.56% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.71%
EPS Next 3Y-30.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BNGO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONANO GENOMICS INC

NASDAQ:BNGO (3/7/2025, 8:08:07 PM)

After market: 3.88 -0.2 (-4.9%)

4.08

-0.02 (-0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-03 2025-03-03/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners16.63%
Inst Owner Change10.83%
Ins Owners0.13%
Ins Owner Change-0.08%
Market Cap11.14M
Analysts47.5
Price Target61.2 (1400%)
Short Float %N/A
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.25%
Min EPS beat(2)-86.74%
Max EPS beat(2)48.24%
EPS beat(4)3
Avg EPS beat(4)9.48%
Min EPS beat(4)-86.74%
Max EPS beat(4)53.93%
EPS beat(8)3
Avg EPS beat(8)-0.45%
EPS beat(12)4
Avg EPS beat(12)-6.7%
EPS beat(16)6
Avg EPS beat(16)-7.43%
Revenue beat(2)0
Avg Revenue beat(2)-14.5%
Min Revenue beat(2)-24.19%
Max Revenue beat(2)-4.8%
Revenue beat(4)1
Avg Revenue beat(4)-7.12%
Min Revenue beat(4)-24.19%
Max Revenue beat(4)1.24%
Revenue beat(8)4
Avg Revenue beat(8)-3.25%
Revenue beat(12)7
Avg Revenue beat(12)-0.7%
Revenue beat(16)11
Avg Revenue beat(16)1.63%
PT rev (1m)5900%
PT rev (3m)5900%
EPS NQ rev (1m)25%
EPS NQ rev (3m)-4400.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-5775.32%
Revenue NQ rev (1m)-1.59%
Revenue NQ rev (3m)-1.59%
Revenue NY rev (1m)-0.35%
Revenue NY rev (3m)-4.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.23
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-68.21
EYN/A
EPS(NY)-12.85
Fwd EYN/A
FCF(TTM)-34.08
FCFYN/A
OCF(TTM)-33.77
OCFYN/A
SpS12.21
BVpS17.9
TBVpS13.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -155.43%
ROE -277.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-56.92%
ROA(5y)-67.49%
ROE(3y)-105.48%
ROE(5y)-252.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.47%
Cap/Sales 2.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.43
Quick Ratio 0.99
Altman-Z -13.43
F-Score2
WACC18.42%
ROIC/WACCN/A
Cap/Depr(3y)20.33%
Cap/Depr(5y)13.26%
Cap/Sales(3y)5.97%
Cap/Sales(5y)3.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1339.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2300%
EPS Next Y-2022.13%
EPS Next 2Y-82.71%
EPS Next 3Y-30.56%
EPS Next 5Y29.12%
Revenue 1Y (TTM)-0.85%
Revenue growth 3Y61.97%
Revenue growth 5Y24.65%
Sales Q2Q%-34.83%
Revenue Next Year-19.94%
Revenue Next 2Y-10.61%
Revenue Next 3Y-1.87%
Revenue Next 5Y30.99%
EBIT growth 1Y39.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.26%
EBIT Next 3Y25.9%
EBIT Next 5YN/A
FCF growth 1Y21.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.46%
OCF growth 3YN/A
OCF growth 5YN/A